It aids in differentiating CK-20 positive cancers, such as colorectal carcinoma, from CK-20 negative tumors, guiding accurate diagnosis and treatment.

Patients with suspected gastrointestinal, bladder, or metastatic cancers of uncertain origin may be recommended for CK-20 testing.

Positive CK-20 staining supports diagnosis of colorectal or urothelial carcinoma, guiding targeted treatment strategies.

A negative result suggests the tumor does not express CK-20, requiring additional markers for accurate diagnosis.

No, medications do not alter protein expression in tissue samples used for immunohistochemistry.

Without testing, cancer origin may remain unclear, delaying accurate diagnosis and treatment planning.